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In this review we discuss the localization and function of the known subtypes of cal-
cium/calmodulin dependent protein kinase IIδ (CaMKIIδ) and their role in cardiac physiology
and pathophysiology. The CaMKII holoenzyme is comprised of multiple subunits that are
encoded by four different genes called CaMKIIα, β, γ, and δ. While these four genes have
a high degree of sequence homology, they are expressed in different tissues. CaMKIIα
and β are expressed in neuronal tissue while γ and δ are present throughout the body,
including in the heart. Both CaMKIIγ and δ are alternatively spliced in the heart to generate
multiple subtypes. CaMKIIδ is the predominant cardiac isoform and is alternatively spliced
in the heart to generate the CaMKIIδB subtype or the slightly less abundant δC subtype.
The CaMKIIδB mRNA sequence contains a 33bp insert not present in δC that codes for an
11-amino acid nuclear localization sequence. This review focuses on the localization and
function of the CaMKIIδ subtypes δB and δC and the role of these subtypes in arrhythmias,
contractile dysfunction, gene transcription, and the regulation of Ca2+ handling.
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EXPRESSION AND LOCALIZATION
Calcium/calmodulin dependent protein kinase II (CaMKII) is a
multimeric enzyme consisting of distinct subunits encoded by
four different genes known as CaMKIIα, β, γ, and δ. These genes
have a high degree of sequence homology but show differential
tissue expression. CaMKIIα and β are predominantly expressed in
neuronal tissue while γ and δ are present throughout the body,
including the heart (Bennett et al., 1983; Tobimatsu and Fuji-
sawa, 1989). CaMKIIδ is the predominant cardiac isoform and
is alternatively spliced to generate multiple subtypes (Edman and
Schulman, 1994).
Schworer et al. (1993) were the ﬁrst to demonstrate that there
are different subtypes of CaMKIIδ expressed in various tissues.
The authors reported four distinct proteins with differential
expression patterns and named them CaMKIIδ1−4. CaMKIIδ2,
and CaMKIIδ3 were shown to be identical except for the inser-
tion of an 11-amino acid sequence in the variable domain of
CaMKIIδ3, the more abundant of the two subtypes in the heart
(Schworer et al., 1993). Around the same time, Edman and
Schulman (1994) identiﬁed these same CaMKIIδ subtypes in rat
heart and characterized their catalytic activity and regulation by
calcium-liganded calmodulin (Ca2+/CaM). They refer to the pre-
dominant cardiac subtypes as CaMKIIδB and CaMKIIδC (the
convention that will be used in this review), which correspond
to the δ3 and δ2 subtypes, respectively. The structure of these
proteins is shown in Figure 1. CaMKIIδB and δC possess simi-
lar catalytic activity and sensitivity to Ca2+/CaM. Furthermore,
both subtypes can undergo autophosphorylation and acquire
a similar degree of Ca2+-independent or autonomous activity
(Edman and Schulman, 1994). In the years that followed, seven
additional splice variants of the CaMKIIδ gene, referred to as
CaMKIIδ5−11, were identiﬁed. Only one of these, CaMKIIδ9, is
expressed in the adult heart (Figure 1; Mayer et al., 1994, 1995;
Hoch et al., 1998, 1999).
The 11-amino acid insert inCaMKIIδB (328KKRKSSSSVQMM)
is also present in some splice variants of CaMKIIα and γ; this con-
servation suggests an important function (Schworer et al., 1993).
Srinivasan et al. (1994) showed that when constructs of CaMKIIδB
are transfected into ﬁbroblasts the expressed protein is localized
to the nucleus. This is not the case for constructs of CaMKIIδC,
implying that that the additional amino acid sequence present in
CaMKIIδB is responsible for nuclear localization (Srinivasan et al.,
1994). A similar differential localization pattern was also observed
when CaMKIIδ subtypes were expressed neonatal rat ventricular
myocytes (NRVMs; Ramirez et al., 1997). Further studies showed
that the 11-amino acid insert in CaMKIIδB can confer nuclear
localization when inserted into the variable domain of CaMKIIα
and that mutagenesis of the ﬁrst two lysines in the insert abro-
gates the nuclear localization of these constructs. Thus it is widely
accepted that the CaMKIIδB variable domain contains a nuclear
localization signal (NLS).
CaMKII heteromultimerization is permissive in that the
CaMKII holoenzyme can include subunits frommultiple CaMKII
genes and multiple splice variants of those genes (Bennett et al.,
1983; Yamauchi et al., 1989). It seems likely that more than a single
CaMKIIδ subtype is present in a single CaMKIIδ multimer and
accordingly the ratio of δB to δC in a multimer could regulate
the localization of the holoenzyme. This has been demonstrated
experimentally. When CaMKIIδB and δC are cotransfected into
ﬁbroblasts orNRVMs, the localization of the expressed protein can
be shifted in accordance with the ratio of the expressed CaMKIIδ
subtypes, i.e., highly expressed δC sequesters δB in the cytosol and
blocks its nuclear localization (Srinivasan et al., 1994; Ramirez
et al., 1997). The opposite is also true: high relative expression
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FIGURE 1 | Domain scheme of CaMKIIδ monomers.The four subtypes
shown are distinguished by the amino acid sequence of a variable region
between the regulatory and association domains. CaMKIIδ2/C lacks this
variable domain while CaMKIIδ3/B contains an 11-amino acid insertion that
contains the canonical nuclear localization signal (NLS) sequence KKRK. An
asterisk denotes a phosphorylation site (Ser332) in this domain that affects
NLS accessibility. CaMKIIδ9 contains a different variable domain sequence
that is also present in the longer variable region of CaMKIIδ1/A. All of these
subtypes can be detected in adult murine heart with the exception of
CaMKIIδ1/A, which is normally only present in neonatal mouse heart.
of δB can localize δC to the nucleus. While not well appreciated,
CaMKIIδB localization can also be regulated by phosphorylation.
A serine (Ser332) immediately adjacent to the NLS of CaMKIIδB
was shown to be a site of phosphorylation byCaMKI andCaMKIV
in vitro. Phosphorylation prevents association of δB with the NLS
receptor m-pendulin and thus limits localization of CaMKIIδB to
the nucleus (Heist et al., 1998). Remarkably this mode of regu-
lation is also seen when the NLS is moved from the middle of
the protein to the N-terminus, suggesting that conformational
changes are not required for phosphorylation to block the NLS.
Relative expression of CaMKIIδ subtypes is altered during car-
diomyocyte differentiation andmaturation and in associationwith
the development of heart failure and ischemia/reperfusion (I/R)
injury (Hoch et al., 1998, 1999; Colomer et al., 2003; Peng et al.,
2010). In humans CaMKIIδB mRNA is selectively upregulated
during heart failure (Hoch et al., 1999). The altered expression
of particular subtypes suggests the possibility of a regulated pro-
cess governing CaMKIIδ mRNA splicing because transcriptional
regulation would not be expected to alter the ratio of CaMKIIδ
subtypes. Alternative splicing factor/pre-mRNA-splicing factor
SF2 (ASF/SF2) was initially described by Krainer and Mani-
atis (1985) and subsequently mice lacking ASF/SF2 expression
were demonstrated to have incomplete processing of CaMKIIδ
mRNA (Krainer and Maniatis, 1985; Xu et al., 2005). Speciﬁcally,
enhanced expression of the δA subtype [δ1 in the nomencla-
ture of Schworer et al. (1993)] was observed while expression
of CaMKIIδB and δC was diminished. Figure 1 also depicts the
structure of the δA subtype, which is expressed in the fetal heart.
ASF/SF2 can be regulated by phosphorylation. Protein kinase A
(PKA)-mediated ASF/SF2 phosphorylation has been correlated
with alternative splicing of CaMKIIδ in heart and brain (Gu et al.,
2011). Additionally, regulation of ASF/SF2 by Protein phosphatase
1 γ (PP1γ) has been demonstrated to affect CaMKIIδ splicing
(Huang et al., 2013). CaMKIIδA expression is increased in models
of isoproterenol-induced cardiac hypertrophy and thus regulation
of CaMKIIδ splicing by PKA and PP1γ may be relevant in the
context of chronic β-adrenergic stimulation (Li et al., 2011). The
RNA binding proteins Fox 1 (RBFOX1) and 2 (RBFOX2) collabo-
rate with ASF/SF2 to induce proper CaMKIIδ splicing (Han et al.,
2011) and factors that regulate these proteins could also inﬂuence
the expression of CaMKIIδ subtypes. Thus, CaMKIIδ splicing is
a dynamic and regulated process. The role of this system in the
heart has not been extensively explored but could be of major
importance since regulation of CaMKIIδ splicing may account for
altered subtype expression andCaMKIIδ signaling in physiological
and pathophysiological settings.
CaMKIIδB TRANSGENIC MICE
The differential localization and function of CaMKIIδ subtypes
could be of considerable importance to understanding the role
of this enzyme in normal physiology and disease states. Early
studies demonstrated that expression of CaMKIIδB in NRVMs
induced atrial natriuretic factor (ANF) expression and led to
increased myoﬁlament organization, both hallmarks of cardiac
hypertrophy, while expression of CaMKIIδC did not (Ramirez
et al., 1997). This ﬁnding suggested that nuclear CaMKIIδ local-
ization is required to regulate gene expression. Consistent with
this notion are data indicating that CaMKIIδB signaling activates
several transcription factors including myocyte enhancer factor
2 (MEF2), GATA4, and heat shock factor 1 (HSF1; Little et al.,
2009; Lu et al., 2010; Peng et al., 2010). The signiﬁcance of the
hypertrophic responses elicited by δB in vitro was explored further
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by generation of CaMKIIδB transgenic (TG) mice (Zhang et al.,
2002). These animals, which overexpress δB under the control of
the cardiac-speciﬁc α-myosin heavy chain (α-MHC) promoter,
demonstrate the enhanced expression of hypertrophic markers
observed in NRVMs expressing CaMKIIδB. CaMKIIδBTG ani-
mals develop hypertrophy and moderate cardiac dysfunction by
4 months of age. Thus, CaMKIIδB expression appears to be suf-
ﬁcient to induce cardiac hypertrophy. Surprisingly, despite the
increased CaMKII activity in the CaMKIIδBTG mouse heart,
phosphorylation of the canonical cardiac CaMKII substrate phos-
pholamban (PLN) at its CaMKII site (Thr17)was not increased but
rather was decreased relative toWTmice. PLN phosphorylation at
the PKA site (Ser16) was similarly reduced. These data were related
to increases in phosphatase activity (Zhang et al., 2002), but also
implied that CaMKIIδB did not lead to robust phosphorylation of
PLN. A subsequent paper that examined CaMKIIδBTG animals at
a younger age to avoid changes in phosphatase activity conﬁrmed
that phosphorylation of PLN and another cardiac CaMKII sub-
strate, the cardiac ryanodine receptor (RyR2), was not increased by
cardiac CaMKIIδB expression (Zhang et al., 2007). This ﬁnding is
consistent with a predominantly nuclear localization and function
of the δB subtype.
CaMKIIδB has also been suggested to regulate expression of the
Na+/Ca2+ exchanger (NCX1) during the development of cardiac
dysfunction following trans-aortic constriction (TAC; Lu et al.,
2011). The conclusion that δB was the subtype involved in NCX1
regulation relied on the use of a constitutively active construct of
CaMKIIδB in which a Thr to Asp mutation (T287D) simulates
autophosphorylation. Interestingly, the authors found that this
construct was excluded from the nucleus (Lu et al., 2010). This dif-
fers from the localizationpatterndescribed above (Srinivasan et al.,
1994; Ramirez et al., 1997) and can be explained as a result of phos-
phorylation of Ser332 in the 11-amino acid insert of δB (Figure 1).
The observation that mutation of Ser332 to Ala restores nuclear
localization of constitutively active CaMKIIδB (Backs et al., 2006)
conﬁrms the role of this site in the cytosolic localization of the
active construct. The possibility that phosphorylation of Ser332
might regulate CaMKIIδB localization in the intact heart has not
been evaluated, but such a mechanism could contribute to the
observation that CaMKIIδB is found outside the nucleus even in
the absence of multimerization with δC (Mishra et al., 2011).
CaMKIIδC TRANSGENIC MICE
CaMKIIδC transgenic mice have also been generated and demon-
strate a strikingly different phenotype from mice that express
CaMKIIδB. While cardiac dysfunction is relatively moderate and
takesmonths to develop inCaMKIIδBTG animals,mice expressing
δC rapidly progress to heart failure and premature death (Zhang
et al., 2003). By 6 weeks of age CaMKIIδCTG animals display
marked changes in cardiac morphology and by 12 weeks these
animals display severe cardiac dysfunction and upregulation of
hypertrophic genes.
Ca2+ HANDING AND ARRHYTHMIA
Expression of the cardiac sarco/endoplasmic reticulum Ca2+-
ATPase (SERCA) is diminished in δCTG mice as occurs in other
models of heart failure. Since SERCA regulates Ca2+ reuptake
into the sarcoplasmic reticulum (SR), this decrease would dimin-
ish SR Ca2+ loading. On the other hand, the CaMKIIδCTG
mice show hyperphosphorylation of PLN at Thr17, which should
improve SERCA function. In addition δCTG animals display
marked increases in phosphorylation of the RyR2, the channel
through which Ca2+ exits the SR. Taken together, these changes
would predict dysregulation of SR Ca2+ cycling and excitation–
contraction coupling. This was substantiated in an accompanying
paper that systematically analyzed and demonstrated dysregula-
tion of cardiac Ca2+ handling in mice expressing δC (Maier et al.,
2003). Speciﬁcally it was shown that SR Ca2+ stores were depleted
in myocytes from these animals, explaining the observation that
isolated myocytes displayed diminished twitch shortening ampli-
tude. Furthermore, Maier et al. (2003) showed that the frequency
and duration of Ca2+ sparks, or spontaneous intracellular Ca2+-
release events, was markedly increased in myocytes from animals
expressing δC. Hyperphosphorylation of RyR2 by CaMKIIδC was
hypothesized to underly the enhanced leak of Ca2+ from the SR,
and this was veriﬁed by the demonstration that acute inhibition
of CaMKII in δCTG myocytes rescues the altered Ca2+ handling
(Maier et al., 2003). In other experiments, acute expression of δC
in rabbit cardiomyocytes was shown to be sufﬁcient to induce SR
Ca2+ sparks and diminished SR Ca2+ loading (Kohlhaas et al.,
2006). These ﬁndings imply that direct regulation of Ca2+ han-
dling targets including RyR2 by CaMKIIδC can account for the
dysregulation of Ca2+ and contractile function seen in myocytes
from δCTG animals (Figure 2).
Dysregulation of excitation–contraction coupling by CaMKII
is thought to contribute to arrythmogenesis in a variety of con-
texts, as supported by the increased incidence of arrhythmogenic
events in CaMKIIδCTG mice (Anderson et al., 1998; Wu et al.,
2002; Wagner et al., 2006). Overexpression of CaMKIIδC not only
induces more spontaneous arrhythmias but also enhances the sus-
ceptibility of mice to arrhythmogenic challenge by β-adrenergic
stimulation. Sag et al. (2009) found that much of the proarrhyth-
mogenic effects of β-adrenergic stimulation on SR Ca2+ leak were
signiﬁcantly inhibited by treatment of myocytes with KN-93, an
inhibitor of CaMKII. Furthermore the SR Ca2+ leak induced
by isoproterenol did not occur in myocytes from mice lacking
CaMKIIδ. These ﬁndings collectively implicate SR Ca2+ leak as
one of the keymechanisms in δC-mediated arrhythmias (Sag et al.,
2009). The notion that hyperphosphorylation of RyR2 at the
CaMKII site (Ser2814) contributes to arrhythmias and SR Ca2+
leak is supported by the ﬁnding that mutation of Ser2814 to Ala
(S2814A) blocks the ability of CaMKII to induce Ca2+ sparks (van
Oort et al., 2010). The autosomal dominant formof catecholamin-
ergic polymorphic ventricular tachycardia (CPVT) can be caused
by theRyR2mutationR4496C andmice carrying thismutation are
predisposed to arrhythmia and ventricular ﬁbrillation. Enhanced
CaMKIIδC expression and activity are implicated in the etiology
of premature death in CPVT as expression of CaMKIIδC exacer-
bates the effects of the R4496C mutation (Dybkova et al., 2011).
As mentioned earlier RyR2 Ser2814 phosphorylation is increased
by expression of CaMKIIδC (but not by δB) in vivo (Zhang et al.,
2007) and the effects of mutating this site (van Oort et al., 2010)
emphasize the importance of RyR2 phosphorylation by CaMKII
in SR Ca2+ leak and arrhythmia.
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FIGURE 2 | Localization and function of CaMKIIδ subtypes in the adult
cardiomyocyte. The circles labeled δC and δB represent CaMKIIδ multimers
that are composed primarily of δC and δB subunits, respectively. Documented
phosphorylation events are indicated by dashed lines. CaMKIIδC regulates
Ca2+ homeostasis and currents involved in arrhythmogenesis through
phosphorylation of Ca2+ handling proteins and channels. CaMKIIδC can also
affect gene transcription through direct and indirect mechanisms including
phosphorylation of NFAT and HDAC (sequestering them in the cytosol),
increases in p53, and increased nuclear import of NF-κB. The CaMKIIδB
subtype has little effect on phosphorylation of Ca2+ handling proteins but
increases gene expression through HDAC phosphorylation and nuclear export
and activation of HSF1 and GATA4. A putative mechanism for δBredistribution
is depicted, showing δBexiting or being excluded from the nucleus due to
phosphorylation at a site (Ser332) adjacent to its NLS.
Other targets besides those at the SR may contribute to
the arrhythmogenic phenotype of CaMKIIδC mice. The car-
diac sodium channel NaV1.5 is physically associated with
CaMKIIδC based on coimmunoprecipitation of these proteins
from CaMKIIδCTG animals and NaV1.5 is phosphorylated in
mice expressing δC (Wagner et al., 2006). CaMKIIδC phospho-
rylates NaV1.5 at multiple sites and phosphorylation appears
to elicit the loss-of-function changes in NaV1.5 gating that are
observed in the context of CaMKIIδC expression in vitro (Ash-
pole et al., 2012; Koval et al., 2012). Incomplete inactivation of
NaV1.5 generates a late Na+ current (INa), which can prolong
the duration of the action potential and contribute to arrhyth-
mias. Additionally, increased INa can lead to Na+-overloading
of the cardiomyocyte, which contributes to diminished dias-
tolic contractile performance (Maltsev et al., 1998). Late INa is
observed in CaMKIIδCTG mice and inhibition of this current
ameliorates arrhythmia and diastolic dysfunction in these ani-
mals (Sossalla et al., 2011). Modulation of INa therefore appears
to contribute to the phenotype of CaMKIIδC mice with respect
to arrhythmia development; additionally the CaMKIIδC subtype
likely regulates the L-type Ca2+ channel (LTCC) and repolarizing
potassium currents (I to and IK1; McCarron et al., 1992; Wagner
et al., 2009). Thus, a multitude of mechanisms link CaMKIIδC to
arrhythmogenesis.
CONTRACTILE DYSFUNCTION
Arrhythmias may contribute to the premature death of
CaMKIIδCTGmice but there are alsomarked decreases in contrac-
tile function in these animals. Since alterations to cardiomyocyte
Ca2+ handling are seen in relatively young CaMKIIδCTG mice
and precede the development of heart failure, it is possible that
dysregulated Ca2+ homeostasis (speciﬁcally SR Ca2+ leak) is an
initiating event in δC-induced heart failure. Speciﬁcally, as a con-
sequence of SR Ca2+ leak and SERCA downregulation, the SR
Ca2+ load is diminished which would compromise contractile
function. To determine whether diminished SR Ca2+ load is the
primary causal event leading to contractile dysfunction and pre-
mature death in response to δC overexpression, we crossed the
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δCTG mice with mice in which the SERCA regulatory protein
PLN was deleted (PLN-KO). Deletion of PLN in the context of
δC overexpression normalized SR Ca2+ levels and the contractile
function of isolated myocytes was restored (Zhang et al., 2010).
Remarkably the development of cardiac dysfunction in vivo was
not rescued but instead was accelerated in the δCTG/PLN-KO
mice. In addition SR Ca2+ leak was enhanced. It was hypoth-
esized that the increased SR Ca2+ load, in the context of RyR2
hyperphosphorylation, precipitated greater Ca2+ leak and further
suggested that the accelerated development of cardiac dysfunction
was due to mitochondrial Ca2+ overloading (Zhang et al., 2010).
These observations and their interpretation places central impor-
tance on the Ca2+ leak elicited by δC-mediated phosphorylation
of RyR2 in the development of heart failure. Further support for
this hypothesis comes from the ﬁnding that CaMKIIδ knockout
mice have attenuated contractile dysfunction in response to pres-
sure overload induced by TAC and myocytes from these animals
show diminished SR Ca2+ leak in response to TAC (Ling et al.,
2009). Additionally, mice expressing the RyR2 S2814A mutation
are protected from the development of heart failure in response
to pressure overload (Respress et al., 2012) consistent with a criti-
cal role for CaMKII-mediated RyR2 phosphorylation.We recently
crossed CaMKIIδC mice with those expressing RyR2 S2814A; if
the hypothesis is correct these mice will show diminished SR
Ca2+ leak and improved contractile function when compared to
CaMKIIδCTG mice.
Another approach used to determine the role of RyR2 phos-
phorylation and SR Ca2+ leak in the phenotype of CaMKIIδCTG
mice was to cross the CaMKIIδCTGmice withmice expressing SR-
targeted autocamtide-2-related inhibitory peptide (SR-AIP; Huke
et al., 2011). AIP simulates the regulatory domain of CaMKII and
inhibits the kinase, and SR-AIP mice have been shown to display
diminished phosphorylation of CaMKII substrates at the SR (Ji
et al., 2003). A reduction in the extent of PLN and RyR2 hyper-
phosphorylation observed in CaMKIIδCTGmice was conferred by
SR-AIP. There were associated changes in Ca2+ handling that indi-
cated amodest improvement in SRCa2+ leak. Despite the salutary
effects of SR-AIP in cells from δCTGmice, in vivo cardiac function
was not improved. One possible explanation for these ﬁndings is
that the degree of inhibition of RyR2 phosphorylation conferred
by SR-AIP was insufﬁcient to prevent the effects of CaMKIIδC
overexpression. Alternatively, while δC-mediated phosphorylation
of targets at the SR including RyR2 and PLN is of considerable
consequence, targets of CaMKII elsewhere in the cell may also
contribute to the pathogenesis of cardiac dysfunction induced by
CaMKIIδC.
Mitochondrial Ca2+ is elevated in mice overexpressing δC
in the context of intact SR Ca2+ load (Zhang et al., 2010) and
increases in mitochondrial Ca2+ are known to induce opening
of the mitochondrial permeability transition pore (MPTP) and
cell death (Halestrap and Davidson, 1990). Considering the cen-
tral importance of mitochondria in the regulation of cell death
and of cell death in the development of heart failure (Wencker
et al., 2003), any pathway by which CaMKIIδC induces mitochon-
drial Ca2+ overloading and subsequent loss of mitochondrial
integrity would be predicted to contribute to the development
of contractile dysfunction and heart failure. To test the role of
mitochondrial dysregulation in the cardiomyopathy that develops
in δCTG animals, CaMKIIδCTGmice were crossed withmice lack-
ing expression of cyclophilin D, a mitochondrial protein required
for the formation of theMPTP. The ability of high Ca2+ to induce
swelling of isolated mitochondria, an index of MPTP opening,
was impaired in the CaMKIIδCTGmice lacking cyclophilin D, but
development of dilated cardiomyopathy and premature death of
these mice was not diminished. Indeed these responses were exac-
erbated when compared to δCTG mice with intact cyclophilin D
expression. The authors suggest that cyclophilin D may actually
play a beneﬁcial role in stress responses, as they observed that TAC-
induced heart failure development was also made more severe by
genetic deletion of cyclophilin D (Elrod et al., 2010). However,
CaMKIIδC is found at mitochondria and a recent seminal study
by Joiner et al. (2012) identiﬁed themitochondrial Ca2+ uniporter
(MCU) as a potential target of CaMKII (Mishra et al., 2011; Joiner
et al., 2012). While phosphorylation of the MCU by CaMKII was
not shown to occur in vivo, a CaMKII-dependent change in the
function of the MCU was evidenced by data demonstrating that a
CaMKII inhibitory peptide targeted to the mitochondria dimin-
ished mitochondrial Ca2+ uptake and inhibited apoptosis in mice
subjected to myocardial infarction and I/R injury.
CaMKIIδ SUBTYPES IN GENE TRANSCRIPTION
The discussion above, and indeed most of the literature, considers
the role of CaMKIIδ-mediated phosphorylation and regulation of
Ca2+ handling proteins and ion channels. Chronic elevations in
CaMKIIδ expression and activity are observed in humans with
heart failure (Hoch et al., 1999) and these long-term changes
are likely to elicit altered gene expression. As discussed ear-
lier, CaMKIIδB induces the expression of hypertrophic genes
in myocytes and transgenic mice, consistent with its primarily
nuclear localization (Ramirez et al., 1997; Zhang et al., 2002).
Other work showed that the CaMKIIδB subtype is required for
GATA-4 binding to the B cell lymphoma 2 (Bcl-2) promoter
and subsequent gene expression (Little et al., 2009). Furthermore,
CaMKIIδB was shown to phosphorylate the transcription factor
HSF1 thereby increasing its transcriptional activity (Peng et al.,
2010). Taken together, these observations imply that it is the
CaMKIIδB subtype that regulates gene expression as a result of
its actions in the nucleus.
It is not necessarily the case, however, that gene regulation
requires CaMKIIδ to be localized to the nuclear compartment.
Despite its primarily cytosolic localization, CaMKIIδC overex-
pressed in mouse heart increased phosphorylation of histone
deacetylase 4 (HDAC4), resulting in activation of the tran-
scription factor MEF2 (Zhang et al., 2007). CaMKIIδC has
also been demonstrated to regulate nuclear localization of
nuclear factor of activated T cells (NFATs) in NRVM. The abil-
ity of CaMKIIδC to decrease nuclear NFAT was blocked by
coexpression of a dominant-negative construct of CaMKIIδC
and was shown to be elicited by phosphorylation and inhi-
bition of the Ca2+/CaM dependent phosphatase calcineurin
(Cn; MacDonnell et al., 2009), presumably in the cytosol. Alter-
ation of Ca2+ homeostasis by cytosolic CaMKIIδC expression
may indirectly affect gene expression and additionally the con-
stitutively active CaMKIIδB utilized in the studies discussed
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above (Lu et al., 2011) is cytosolic and yet regulates expression
of NCX1.
Regulation of gene expression by CaMKIIδB has been demon-
strated to promote cardiomyocyte survival while the opposite is
true for CaMKIIδC. CaMKIIδB was shown to protect cardiomy-
ocytes from doxorubicin-induced cell death via transcriptional
upregulation of Bcl-2 (Little et al., 2009). Along similar lines,
CaMKIIδB contributes to cardioprotection fromH2O2 by increas-
ing inducible heat shock protein 70 (iHSP70) expression (Peng
et al., 2010). Conversely, CaMKIIδC activation is implicated in
cell death elicited by a variety of stimuli (Zhu et al., 2007). It
has been suggested that CaMKIIδC (but not δB) upregulates the
proapoptotic transcription factor p53 (Toko et al., 2010), and
recent work from our laboratory demonstrates that CaMKIIδC
expression inNRVMs activates the proinﬂammatory transcription
factor nuclear factor κB (NF-κB; Ling et al., 2013). We demon-
strated that CaMKIIδC increased phosphorylation of IκB Kinase
(IKK) and since IKK activation can also upregulate p53(Jia et al.,
2013), this pathway may contribute to the proapoptotic response
reported by Toko et al. (2010).
FUTURE DIRECTIONS
There is compelling evidence that the CaMKIIδB and δC sub-
types differentially regulate cardiomyocyte Ca2+ handling and
survival in vitro. Whether this occurs in vivo under physiological
or pathophysiological conditions, and whether δB and δC sub-
serve different functions based on their localization or selective
activation, remains to be determined.
It seems likely that the relative levels of endogenous δB and δC
determine localization and could therefore impact CaMKIIδ sig-
naling. Hypothetically, a selective increase in CaMKIIδC would
result in accumulation of cytosolic CaMKIIδ and depletion of
nuclear CaMKIIδ while a selective increase in CaMKIIδB would
have the opposite effect. CaMKIIδ redistribution in this manner
may contribute to the phenotype of mice that overexpress δB and
δC and importantly there are changes in the relative expression of
δB and δC inmodels of heart failure and I/R injury. In bothmodels
δC expression is enhanced relative to that of δB (Zhang et al., 2003;
Peng et al., 2010). It is not known how this occurs but it is of inter-
est to postulate that in heart failure and during I/R regulation of
CaMKIIδ splicing is altered. ASF/SF2 and RBFOX1/2 regulate the
splicing of theCaMKIIδ gene and thus expression of δB and δC, but
whether changes in splicing occur in and contribute to the devel-
opment of heart failure or I/R injury remains to be determined. It
is likely that the increased δC expression observed in these models
is pathogenic.
While CaMKIIδB contains an NLS, this subtype is not com-
pletely sequestered in the nucleus (Mishra et al., 2011). As men-
tioned previously the NLS within the variable domain of δB can be
regulatedbyphosphorylation,whichprevents nuclear localization.
This type of regulation could be of considerable importance since
the nuclear localization of δB appears to correlate with enhanced
expression of protective genes and cell survival while cytosolic
localization does not (Little et al., 2009; Peng et al., 2010; Lu et al.,
2011).
Of additional interest is the neglected CaMKIIδ9. The pio-
neering work of (Hoch et al., 1998; Mayer et al., 1995) identiﬁed
δ9 as one of the three subtypes of CaMKIIδ in the adult heart
and showed that it is expressed at similar levels to those of
CaMKIIδB. δ9 contains a sequence (328EPQTTVIHNPDGNK) not
present in δB or δC and thus may possess unique properties that
merit further investigation, as the function and localization of δ9
in vivo has not been explored. Along similar lines, CaMKIIδA
expression is increased in a model of cardiac hypertrophy (Li
et al., 2011), but the possibility that this splice variant is upreg-
ulated in and contributes to cardiovascular disease has not been
investigated.
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